2QK Stock Chart & Stats
€49.24
€1.40(3.34%)
At close: 4:00 PM EDT
€49.24
€1.40(3.34%)
Day’s Range― - ―
52-Week Range€23.00 - €50.16
Previous CloseN/A
Volume80.00
Average Volume (3M)7.00
Market Cap
€6.28B
Enterprise Value€6.90K
Total Cash (Recent Filing)€492.09M
Total Debt (Recent Filing)€203.83M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 18, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding121,785,280
10 Day Avg. Volume18
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€53.78Price Target Upside9.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.84
Revenue Forecast (FY)€4.97M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress And Manufacturing RedundancyThe accepted BLA and defined FDA decision date create a clear regulatory path, while two fill/finish facilities reduce dependence on one supplier. This combination can improve launch resilience if one manufacturing site faces inspection or execution delays.
Clinical Efficacy And Pipeline ExpansionPositive pivotal efficacy and advancing follow-on studies support apitegromab's clinical foundation while broadening the pipeline. Multiple programs could create additional development value and reduce reliance on a single candidate over the medium term.
Liquidity And Financing FlexibilityA substantial cash balance, additional borrowing capacity and potential voucher proceeds provide resources to fund regulatory preparation, launch activities and clinical development. This extends strategic flexibility despite the company's substantial operating cash needs.
Bears Say
No Current Commercial RevenueThe company remains dependent on financing and potential collaboration proceeds because it has not yet generated product revenue. Until apitegromab is approved and adopted, losses are likely to continue and operating performance remains exposed to development outcomes.
Heavy Cash Burn And Rising DebtPersistent cash consumption alongside sharply higher debt can reduce financial flexibility and increase dependence on equity, borrowing or asset monetization. If launch revenue is delayed, further funding could be needed before the business becomes self-sustaining.
Approval And Market-access Execution RiskUnresolved manufacturing inspection status can affect U.S. and European approval timing, while payer authorization may slow early patient starts after approval. These execution barriers could delay revenue conversion even if clinical and regulatory milestones are achieved.
Scholar Rock Holding News
2QK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was €23.00 and its highest was €50.16 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is €6.28B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is Nov 18, 2026 which is in 82 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Aug 06, 2026. The company reported -€0.719 earnings per share for the quarter, beating the consensus estimate of -€0.719 by <€0.001.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.73.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 121,785,280 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -€0.719 in its last earnings report, beating expectations of -€0.719. Following the earnings report the stock price went up 1.073%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Currently, no hedge funds are holding shares in DE:2QK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€53.78 (9.23% Upside)
€53.78 (9.23% Upside)
Blogger Sentiment
Bullish
DE:2QK Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
53.96%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
2QK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong forward momentum: the BLA is accepted with a fixed PDUFA date, management has established two independent manufacturing paths (reducing single-site risk), commercial operations are launch-ready, the pipeline is advancing (Phase II OPAL recruitment, FORGE initiated, SRK-439 dosing), and the company finished the quarter with a healthy cash balance and financing optionality. Main negatives are the outstanding FDA inspection classification for Catalent Indiana (which also affects EMA timing), ongoing third-party manufacturing/regulatory timing risk, and expected payer/reimbursement friction that could delay patient access after approval. On balance, the positive regulatory progress, commercial preparedness, clinical achievements and solid cash position outweigh the operational and reimbursement risks discussed on the call.View all DE:2QK earnings summaries2QK Stock 12 Month Forecast
Average Price Target
€53.78
▲(9.23% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―